Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRX004 · NN-6019

Monoclonal antibody · Acts on transthyretin (TTR) · developed by Prothena Biosciences

Phase 1 Most advanced trial (none active)
PRTA Developer
1 Registered trials

What is PRX004?

PRX004 (also known as NN-6019) is an intravenously given agent studied in transthyretin (ATTR) amyloidosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NN-6019
Drug type
Monoclonal antibody
Targets
transthyretin (TTR)
Mechanism
Acts on transthyretin (TTR)
Therapy area
Metabolic
Developer
Prothena Biosciences Limited (PRTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
1D57NC901Z

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03336580 Phase 1 Amyloidogenic Transthyretin (ATTR) Amyloidosis Terminated PRTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyloidogenic Transthyretin (ATTR) Amyloidosis

Other drugs acting on TTR

More from Prothena Biosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRTA page.

Follow PRTA, the company behind PRX004

See PRTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.